CA2230991A1 - Demethylase de l'adn et utilisations therapeutiques et diagnostiques connexes - Google Patents
Demethylase de l'adn et utilisations therapeutiques et diagnostiques connexes Download PDFInfo
- Publication number
- CA2230991A1 CA2230991A1 CA 2230991 CA2230991A CA2230991A1 CA 2230991 A1 CA2230991 A1 CA 2230991A1 CA 2230991 CA2230991 CA 2230991 CA 2230991 A CA2230991 A CA 2230991A CA 2230991 A1 CA2230991 A1 CA 2230991A1
- Authority
- CA
- Canada
- Prior art keywords
- demethylase
- dna
- cdna
- expression
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 title claims abstract description 141
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 title claims abstract description 141
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 201000011510 cancer Diseases 0.000 claims abstract description 19
- 102000004190 Enzymes Human genes 0.000 claims abstract description 10
- 108090000790 Enzymes Proteins 0.000 claims abstract description 10
- 108020004414 DNA Proteins 0.000 claims description 71
- 239000002299 complementary DNA Substances 0.000 claims description 62
- 210000004027 cell Anatomy 0.000 claims description 40
- 238000000338 in vitro Methods 0.000 claims description 31
- 230000014509 gene expression Effects 0.000 claims description 29
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 230000011987 methylation Effects 0.000 claims description 16
- 238000007069 methylation reaction Methods 0.000 claims description 16
- 238000003556 assay Methods 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- 229940104302 cytosine Drugs 0.000 claims description 11
- 230000000692 anti-sense effect Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 239000000523 sample Substances 0.000 claims description 8
- 238000010367 cloning Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 6
- 239000013610 patient sample Substances 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 4
- 238000001415 gene therapy Methods 0.000 claims description 4
- 238000013537 high throughput screening Methods 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 claims description 3
- 230000007067 DNA methylation Effects 0.000 claims description 3
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 230000009395 genetic defect Effects 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 230000001594 aberrant effect Effects 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 238000010370 cell cloning Methods 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 238000012937 correction Methods 0.000 claims description 2
- 238000013461 design Methods 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000010396 two-hybrid screening Methods 0.000 claims description 2
- 229940122680 Demethylase inhibitor Drugs 0.000 claims 1
- 230000003172 anti-dna Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 description 18
- 239000000872 buffer Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- 108020004635 Complementary DNA Proteins 0.000 description 8
- 230000017858 demethylation Effects 0.000 description 7
- 238000010520 demethylation reaction Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 206010011878 Deafness Diseases 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108010063593 DNA modification methylase SssI Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 125000000086 dCMP group Chemical group 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- OBCJQWSXSLYWHI-WKSZEZMPSA-N dCpdG Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 OBCJQWSXSLYWHI-WKSZEZMPSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 108010023571 hylase Proteins 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2230991 CA2230991A1 (fr) | 1998-05-11 | 1998-05-11 | Demethylase de l'adn et utilisations therapeutiques et diagnostiques connexes |
| US09/554,414 US7098012B1 (en) | 1997-11-12 | 1998-11-12 | DNA demethylase, therapeutic and diagnostic uses thereof |
| AU11386/99A AU1138699A (en) | 1997-11-12 | 1998-11-12 | Dna demethylase, therapeutic and diagnostic uses thereof |
| JP2000520577A JP2001522607A (ja) | 1997-11-12 | 1998-11-12 | Ｄｎａデメチラーゼおよびその治療および診断用途 |
| PCT/CA1998/001059 WO1999024583A1 (fr) | 1997-11-12 | 1998-11-12 | Adn demethylase, utilisations therapeutiques et diagnostiques de celle-ci |
| CA002309361A CA2309361A1 (fr) | 1997-11-12 | 1998-11-12 | Adn demethylase, utilisations therapeutiques et diagnostiques de celle-ci |
| EP98954092A EP1029058A1 (fr) | 1997-11-12 | 1998-11-12 | Adn demethylase, utilisations therapeutiques et diagnostiques de celle-ci |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2230991 CA2230991A1 (fr) | 1998-05-11 | 1998-05-11 | Demethylase de l'adn et utilisations therapeutiques et diagnostiques connexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2230991A1 true CA2230991A1 (fr) | 1999-11-11 |
Family
ID=29409371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2230991 Abandoned CA2230991A1 (fr) | 1997-11-12 | 1998-05-11 | Demethylase de l'adn et utilisations therapeutiques et diagnostiques connexes |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2230991A1 (fr) |
-
1998
- 1998-05-11 CA CA 2230991 patent/CA2230991A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1618212B1 (fr) | Mutations du gene humain pcsk9 qui sont associees a la hypercholesterolemia | |
| Tu et al. | Embryonic and hematopoietic stem cells express a novel SH2–containing inositol 5′-phosphatase isoform that partners with the Grb2 adapter protein | |
| US7829671B2 (en) | Gene encoding a DNA repair enzyme and methods of use thereof | |
| JP2004526444A (ja) | Ｓｔｅａｐ関連タンパク質 | |
| US5945522A (en) | Prostate cancer gene | |
| JP2003507061A (ja) | ＵＤＰ−Ｎ−アセチルグルコサミン：ガラクトース−β１，３−Ｎ−アセチル−ガラクトサミン−α−Ｒ／（ＧｌｃＮＡｃ：ＧａｌＮＡｃ）β１，６−Ｎ−アセチルグルコサミニルトランスフェラーゼ，Ｃ２ＧｎＴ３ | |
| KR100828506B1 (ko) | 마우스 정자 형성 유전자와 인간 남성 불임 관련 유전자,및 이들을 사용한 진단 시스템 | |
| AU2003290715A1 (en) | Method for identifying risk of melanoma and treatments thereof | |
| JP2003510349A (ja) | 線条体機能に必要な遺伝子、その使用、およびそれを調節するための化合物 | |
| Yang et al. | Cloning and expression pattern of a spermatogenesis-related gene, BEX1, mapped to chromosome Xq22 | |
| US6599728B2 (en) | Second mammalian tankyrase | |
| US7098012B1 (en) | DNA demethylase, therapeutic and diagnostic uses thereof | |
| EA005921B1 (ru) | Ген и белок, ассоциированные с шизофренией | |
| JP2005505237A (ja) | スルファターゼおよびそれらの使用の方法 | |
| Van Roy et al. | Localization of the 17q breakpoint of a constitutional 1; 17 translocation in a patient with neuroblastoma within a 25‐kb segment located between the ACCN1 and TLK2 genes and near the distal breakpoints of two microdeletions in neurofibromatosis type 1 patients | |
| CA2230991A1 (fr) | Demethylase de l'adn et utilisations therapeutiques et diagnostiques connexes | |
| CN117441019A (zh) | 用干扰素诱导的解旋酶c结构域1(ifih1)抑制剂治疗银屑病 | |
| US20030167480A1 (en) | NDR2-related proteins | |
| Groet et al. | Narrowing of the region of allelic loss in 21q11‐21 in squamous non‐small cell lung carcinoma and cloning of a novel ubiquitin‐specific protease gene from the deleted segment | |
| US5977333A (en) | DNA sequence encoding the myotonic dystrophy gene and uses thereof | |
| US20020137038A1 (en) | Intestinal proteins | |
| JP2001512007A (ja) | Ｚｇｇｂｐ１、１型双極性感情障害に関与する新規ペプチド、配列及びその使用 | |
| Cappelli et al. | Repair of 8 oxoguanine in mammalian cells expressing the Drosophila S3 ribosomal/repair protein | |
| CA2261637A1 (fr) | Gene humain contre la progression du cycle cellulaire et la radioresistance | |
| JP2005503107A (ja) | Ａｓｉｐ関連タンパク質 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |